Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Subthalamic stimulation for Parkinson's disease.

Zvi Israel1, Sharon Hassin-Baer

  • 1Department of Neurosurgery, Hadassah University Hospital, Jerusalem, Israel. israelz@hadassah.org.il

The Israel Medical Association Journal : IMAJ
|July 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploratory Prospective Study of Self-Titrated Medical Cannabis for Nonmotor Symptoms in Parkinson's Disease.

Cannabis and cannabinoid research·2026
Same author

Rare-Variant Burden across Lysosomal Genes Implicates Sialylation and Ganglioside Metabolism in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Resolution of chronic refractory migraine and development of burning mouth syndrome after focused ultrasound thalamotomy: illustrative case.

Journal of neurosurgery. Case lessons·2026
Same author

The GBA1 p.E427K (p.E388K) Variant Is a Risk Factor for Synucleinopathies: A Meta-Analysis.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.

Neurology and therapy·2026
Same author

The <i>GBA1</i> p.E427K (p.E388K) Variant is a Risk Factor for Synucleinopathies: A Meta-Analysis.

medRxiv : the preprint server for health sciences·2026

Deep brain stimulation of the subthalamic nucleus is an effective Parkinson's disease therapy. This treatment improves motor function, quality of life, and reduces medication needs in suitable patients.

Area of Science:

  • Neurology
  • Neurosurgery
  • Biomedical Engineering

Background:

  • Parkinson's disease is a progressive neurodegenerative disorder affecting motor control.
  • Subthalamic nucleus deep brain stimulation (DBS) has emerged as a significant therapeutic option.

Purpose of the Study:

  • To review the indications for subthalamic nucleus stimulation in Parkinson's disease.
  • To outline the surgical technique and postoperative management protocols.

Main Methods:

  • Review of current literature and clinical practices regarding subthalamic nucleus DBS.
  • Analysis of patient selection criteria and outcomes.

Main Results:

  • Subthalamic nucleus stimulation effectively treats cardinal Parkinson's disease symptoms.

Related Experiment Videos

  • Patients experience significant motor improvements and enhanced quality of life.
  • Reduced medication dependency is observed post-stimulation.

    • Conclusions:

    • Subthalamic nucleus stimulation is a highly effective intervention for Parkinson's disease.
    • Careful patient selection and management are crucial for optimal outcomes.